ROCKVILLE, MD., Sept. 8, 2016 -- The Regulatory Affairs Professionals Society (RAPS) today announced six regulatory experts have joined the elite ranks of RAPS Fellows. The 2016 Fellows will be honored Tuesday, 20 September, during RAPS' Regulatory Convergence conference in San Jose, CA. The Convergence is the largest annual gathering of the global regulatory profession, and RAPS' signature annual event.
The RAPS Fellows program recognizes senior regulatory professionals for their continued contributions and leadership toward the advancement of the profession and the professional. Being named a RAPS Fellow is a significant accomplishment within the regulatory profession. RAPS Fellows serve as important resources for knowledge and guidance to the organization and the profession as a whole. They may use the FRAPS designation following their names.
The 2016 RAPS Fellows are:
• Ayse Baker, FRAPS, global regulatory affairs head, GE Healthcare
• Meredith Brown-Tuttle, RAC, FRAPS, vice president, regulatory and quality, Lyric Pharmaceuticals Inc.; CEO, Regulatorium
• Nicole Landreville, RAC, FRAPS, regulatory affairs program manager, GE Healthcare
• Erin Oliver, RAC, FRAPS, global regulatory lead, Rx-to-OTC switch, GSK Consumer Healthcare
• Debra Rasmussen, RAC, FRAPS, global regulatory affairs diagnostic leader/senior director, Janssen Pharmaceutical
• Kimberly Walker, RAC, FRAPS, global RA and QA consultant, Kim Walker Consulting
More information about the Regulatory Convergence and a complete agenda of sessions and events is available at www.RAPS.org/Convergence. The Twitter hashtag for the conference is #2016RAPS.
Reporters, bloggers and other members of the media who wish to cover all or part of RAPS' Regulatory Convergence should contact Zachary Brousseau, senior manager, communications for RAPS at [email protected] or +1 301 770 2920, ext. 245. On-site registration also will be available for media with valid press credentials or a letter from an assigning editor.
About RAPS
The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC), the only post-academic professional credential to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with offices in Shanghai and Singapore, and chapters and affiliates worldwide. RAPS.org
CONTACT: Zachary Brousseau
Senior Manager, Communications, RAPS
+1 301 770 2920, ext. 245
[email protected]


Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users 



